Atebimetinib with modified chemo led to 94% 6-month survival charges in first-line pancreatic most cancers: © inventory.adobe.com.
Atebimetinib (IMM-1-104) together with modified chemotherapy (Gemzar plus Abraxane [gemcitabine/nab-paclitaxel]) demonstrated sturdy responses in first-line sufferers with pancreatic most cancers, in keeping with a information launch from Immuneering Company.
“These distinctive information reveal the potential of atebimetinib plus [chemotherapy] to dramatically lengthen the lives of sufferers with superior pancreatic most cancers,” Ben Zeskind, co-founder and chief govt officer of Immuneering, mentioned within the information launch. “A 94% general survival [rate] at six months is outstanding in first-line pancreatic most cancers sufferers. Atebimetinib was designed to ship distinctive sturdiness and tolerability to a broad vary of sufferers with completely different cancers, and it’s deeply gratifying to see proof of that enjoying out first in one of the aggressive and lethal sorts of most cancers. Our final aim is to assist most cancers sufferers outlive their illness, and immediately’s announcement represents an vital milestone on that journey.”
Glossary:
Total survival: time from remedy begin till dying from any trigger.
Development-free survival: time throughout and after remedy {that a} affected person lives with out most cancers rising or spreading.
Total response price: proportion of sufferers whose most cancers shrinks or disappears after remedy.
Illness management price: proportion of sufferers who’ve most cancers shrinkage or stabilization after remedy.
Sturdy response: a long-lasting constructive impact from remedy on most cancers.
As of Could 26, 2025, a 94% general survival price at six months was noticed in sufferers with beforehand untreated pancreatic most cancers who acquired atebimetinib on the 320 milligrams (mg) once-daily dose plus modified gemcitabine and nab-paclitaxel (34 sufferers). By comparability, the everyday six-month survival price for sufferers receiving standard-dose gemcitabine and nab-paclitaxel is 67%. Median general survival had not but been reached on the time of study.
Development-free survival at six months was 72% in the identical group, in contrast with the 44% benchmark for normal remedy. Median progression-free survival was additionally not but reached. Amongst 36 response-evaluable sufferers handled at each the 240 mg and 320 mg dose ranges of atebimetinib with modified gemcitabine and nab-paclitaxel, the general response price was 39% and the illness management price was 81%. Many sufferers skilled deep, long-lasting tumor shrinkage, with a number of particular person tumors turning into undetectable on scans.
“These information clearly set up atebimetinib’s potential as a extra sturdy and higher tolerated MEK inhibitor positioned to assist sufferers each reside longer and reside higher, with thrilling potential alternatives in pancreatic most cancers and quite a lot of different cancers,” Dr. Igor Matushansky, chief medical officer of Immuneering, mentioned within the information launch. “We look ahead to advancing atebimetinib to a pivotal trial as quickly as potential.”
Security Knowledge and Future Instructions of Remedy
Atebimetinib continued to point out a positive security profile when mixed with modified gemcitabine and nab-paclitaxel. Most typical unwanted side effects sometimes seen with normal chemotherapy have been both gentle or absent, with few extreme unwanted side effects reported.
Based mostly on these findings, the trial’s enrollment goal for this remedy mixture in newly identified pancreatic most cancers has been elevated to approximatley 50 sufferers, in keeping with the discharge.
These distinctive information reveal the potential of atebimetinib plus [chemotherapy] to dramatically lengthen the lives of sufferers with superior pancreatic most cancers.
Constructing on these new section 2a scientific information, Immuneering plans a number of upcoming milestones for atebimetinib. Regulatory suggestions on pivotal research plans is predicted in late 2025, together with extra information from the section 2a trial. The corporate additionally plans to launch a pivotal randomized trial of atebimetinib plus mGnP in first-line pancreatic most cancers in 2026, in addition to provoke extra mixture trial arms that very same yr.
“The encouraging scientific information reported to this point for atebimetinib signify a possible new and considerably extra sturdy remedy choice for pancreatic most cancers sufferers, for whom restricted therapeutic choices are at the moment obtainable,” Dr. Vincent Chung, a professor within the Division of Medical Oncology and Therapeutics Analysis at Metropolis of Hope, and principal investigator of the section 2a scientific trial, mentioned within the information launch.
“I’ve handled pancreatic most cancers sufferers with atebimetinib who’ve skilled distinctive sturdiness. Present normal of care therapies in pancreatic most cancers will be related to restricted sturdiness and extreme unwanted side effects, resulting in poor affected person outcomes. We now have not seen vital enchancment in normal of care for many years, and there’s an pressing want for extra sturdy and higher tolerated new remedies that assist sufferers reside longer,” Chung concluded.
Reference
“Immuneering Stories Optimistic Total Survival Knowledge for Atebimetinib (IMM-1-104) from Ongoing Part 2a Trial in First-Line Pancreatic Most cancers Sufferers.” Press launch. Immuneering Company. June 17, 2025.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
